There is no cure for life, according to an old aphorism. Wealthy investors are more hopeful of extending average lifespans — perhaps indefinitely — despite years of disappointment.
OpenAI co-founder Sam Altman may be among those intending to thumb his nose at the Grim Reaper for longer. His reported $180mn investment in San Francisco’s Retro Bioscience proves that interest in anti-ageing start-ups remains healthy.
Most bioscience start-ups focus on healthier old age, though some are investigating immortality via cryopreservation. One recent Thiel Fellow, part of a group awarded $100,000 to drop out of formal education and start a company, plans to offer cryonics for pets too.
您已閱讀34%（682字），剩餘66%（1315字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。